Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04772989
Recruitment Status : Recruiting
First Posted : February 26, 2021
Last Update Posted : October 7, 2021
Sponsor:
Information provided by (Responsible Party):
Arcus Biosciences, Inc.

Brief Summary:
This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumor NSCLC Melanoma Cervical Cancer Multiple Myeloma Lymphoma, Non-Hodgkin DLBCL Gastric Cancer Gastroesophageal Junction Adenocarcinoma Esophageal Cancer Drug: AB308 Drug: Zimberelimab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 154 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies
Actual Study Start Date : March 19, 2021
Estimated Primary Completion Date : June 2023
Estimated Study Completion Date : December 2023


Arm Intervention/treatment
Experimental: Dose Escalation Q3W Cohorts
Escalating doses of AB308 in combination with zimberelimab (360 mg) will be given every 3 weeks in participants with advanced malignancies.
Drug: AB308
Administered as specified in the treatment arm

Drug: Zimberelimab
Administered as specified in the treatment arm
Other Name: AB122

Experimental: Dose Escalation Q4W Cohorts
Escalating doses of AB308 in combination with zimberelimab (480 mg) will be given every 4 weeks in participants with advanced malignancies.
Drug: AB308
Administered as specified in the treatment arm

Drug: Zimberelimab
Administered as specified in the treatment arm
Other Name: AB122

Experimental: Dose Expansion Cohort 1
AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with in participants with locally advanced or metastatic NSCLC.
Drug: AB308
Administered as specified in the treatment arm

Drug: Zimberelimab
Administered as specified in the treatment arm
Other Name: AB122

Experimental: Dose Expansion Cohort 2
AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with melanoma.
Drug: AB308
Administered as specified in the treatment arm

Drug: Zimberelimab
Administered as specified in the treatment arm
Other Name: AB122

Experimental: Dose Expansion Cohort 3
AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with metastatic gastric, or gastroesophageal junction, or esophageal cancer.
Drug: AB308
Administered as specified in the treatment arm

Drug: Zimberelimab
Administered as specified in the treatment arm
Other Name: AB122

Experimental: Dose Expansion Cohort 4
AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with cervical cancer.
Drug: AB308
Administered as specified in the treatment arm

Drug: Zimberelimab
Administered as specified in the treatment arm
Other Name: AB122

Experimental: Dose Expansion Cohort 5
AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with hematological malignancies.
Drug: AB308
Administered as specified in the treatment arm

Drug: Zimberelimab
Administered as specified in the treatment arm
Other Name: AB122




Primary Outcome Measures :
  1. Percentage of participants with Adverse Events [ Time Frame: From first study treatment administration until up to 90 days after the last dose (Approximately 1 year) ]
  2. Percentage of participants who experience a Dose Limiting Toxicity [ Time Frame: From first study treatment administration through Day 21 (Q3W arm) or Day 28 (Q4W arm) ]

Secondary Outcome Measures :
  1. Serum concentration of AB308 [ Time Frame: Recorded at baseline (day 1 of cycle 1), during each of the first 5 cycles (each cycle is 21 days or 28 days) )and up to the first 16 cycles of treatment (up to 15 months), and 30 and 90 days post last dose (i.e. in total up to approximately 18 months). ]
  2. Serum concentration of zimberelimab [ Time Frame: Recorded at baseline (day 1 of cycle 1), during each of the first 5 cycles (each cycle is 21 days or 28 days) and up to the first 16 cycles of treatment (up to 15 months), and 30 and 90 days post last dose (i.e. in total up to approximately 18 months). ]
  3. Percentage of participants with anti-drug antibodies to AB308 [ Time Frame: Recorded at baseline (day 1 of cycle 1), during each of the first 4 cycles (each cycle is 21 days or 28 days) and up to the first 16 cycles of treatment (up to 15 months), and 30 and 90 days post last dose (i.e. in total up to approximately 18 months). ]
  4. Percentage of participants with anti-drug antibodies to zimberelimab [ Time Frame: Recorded at baseline (day 1 of cycle 1), during each of the first 4 cycles (each cycle is 21 days or 28 days) and up to the first 16 cycles of treatment (up to 15 months), and 30 and 90 days post last dose (i.e. in total up to approximately 18 months). ]
  5. Percentage of participants with Objective Response [ Time Frame: From study enrollment until participant discontinuation, first occurrence of progressive disease, or death from any cause, whichever occurs first (up to approximately 3-5 years) ]
  6. Duration of Response [ Time Frame: From the date of first occurrence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years) ]
  7. Percentage of Participants with Disease Control (complete response, partial response, or stable disease) for >6 months [ Time Frame: From study enrollment until disease progression or loss of clinical benefit (up to approximately 3-5 years) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  • Performance status score of 0 or 1
  • Measurable disease as per radiographic evaluation
  • Disease-specific criteria for dose escalation:

    • Participants with any type of solid tumor for which no treatment is currently available, or
    • Participants with non-Hodgkin Lymphoma that has progressed on prior chemotherapy and have not or are unable to receive stem cell transplant. transfer
    • Participants may have received up to 5 prior anti-cancer therapies and an unlimited number of prior hormonal therapies.
  • Disease-specific criteria for dose-expansion Cohort 1:

    • Participants with previously untreated locally advanced or metastatic NSCLC with a high PD-L1 expression
  • Disease-specific criteria for dose-expansion Cohort 2:

    • Participants with metastatic melanoma with at least one prior anti-cancer therapy and progression after PD-L1 therapy
  • Disease-specific criteria for dose-expansion Cohort 3:

    • Participants with metastatic gastric, or gastroesophageal junction, or esophageal cancer with at least 1 prior chemotherapy and no prior PD-(L)1 therapy.
  • Disease-specific criteria for dose-expansion Cohort 4:

    • Participants with metastatic cervical cancer with at least 1 prior chemotherapy and no prior PD-(L)1 therapy.
  • Disease-specific criteria for dose-expansion Cohort 5

    • Participants with diffuse large B-cell lymphoma (DLBCL) with at least 2 prior anti-cancer therapies and have not or are unable to receive allogenic stem cell transplant
    • Participants with multiple myeloma with at least 3 prior anti-cancer therapies and for whom no treatment is currently available.

Exclusion Criteria:

  • History of trauma or major surgery within 28 days prior to the first dose of study treatment.
  • Prior treatment with an anti-TIGIT antibody.
  • Any active or prior autoimmune disease that required treatment within 3 years of the first dose of study treatment.
  • Prior chemotherapy, targeted small-molecule therapy, immunotherapy, or biologic agents, or use of other investigational drugs within 28 days before first dose of study treatment.
  • Discontinued prior immunotherapy for immune related adverse events with a high severity.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04772989


Contacts
Layout table for location contacts
Contact: Arcus Biosciences 510-694-6200 clinicaltrials@arcusbio.com

Locations
Show Show 20 study locations
Sponsors and Collaborators
Arcus Biosciences, Inc.
Investigators
Layout table for investigator information
Study Director: Medical Director Arcus Biosciences
Layout table for additonal information
Responsible Party: Arcus Biosciences, Inc.
ClinicalTrials.gov Identifier: NCT04772989    
Other Study ID Numbers: ARC-12
First Posted: February 26, 2021    Key Record Dates
Last Update Posted: October 7, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Plasma Cell
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Lymphoma
Lymphatic Diseases